Get the Stockscreener App
12.31
6.49%
0.75
After Hours:
12.33
0.02
+0.16%
Erasca Inc stock is traded at $12.31, with a volume of 3.34M.
It is up +6.49% in the last 24 hours and up +97.59% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$11.56
Open:
$11.87
24h Volume:
3.34M
Relative Volume:
0.69
Market Cap:
$3.81B
Revenue:
-
Net Income/Loss:
$-127.69M
P/E Ratio:
-27.31
EPS:
-0.4508
Net Cash Flow:
$-98.43M
1W Performance:
+3.62%
1M Performance:
+97.59%
6M Performance:
+689.10%
1Y Performance:
+684.08%
1-Day Range:
$11.65
$12.57
1-Week Range:
$11.40
$12.57
52-Week Range:
$1.01
$12.57
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
12.31 | 3.58B | 0 | -127.69M | -98.43M | -0.4508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Resumed | Mizuho | Outperform |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Erasca (NASDAQ:ERAS) Trading Up 6.8%Should You Buy? - MarketBeat
Erasca stock reaches 52-week high at 12.48 USD - Investing.com
ERAS: Early clinical data show promising efficacy and safety for next-generation pan-RAS and pan-KRAS inhibitors - TradingView
Erasca Sees Unusually High Options Volume (NASDAQ:ERAS) - MarketBeat
What sentiment indicators say about Erasca Inc. stock2025 Growth vs Value & Weekly Breakout Watchlists - mfd.ru
Erasca (NASDAQ:ERAS) Sets New 1-Year HighStill a Buy? - MarketBeat
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target - Investing.com Nigeria
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target By Investing.com - Investing.com South Africa
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike - MSN
Erasca (ERAS) Is Up 15.2% After Upsized Offering Extends Cash Runway For RAS/MAPK Pipeline - simplywall.st
Erasca (NASDAQ:ERAS) Trading 6.4% HigherHere's What Happened - MarketBeat
Erasca to Present at Upcoming Conferences in February - The Manila Times
Erasca (ERAS) Price Target Increased by 60.94% to 10.51 - Nasdaq
Erasca (ERAS) Is Up 10.4% After $225M Follow-On Offering And RAS Pipeline UpdatesHas The Bull Case Changed? - Yahoo Finance
Erasca (NASDAQ:ERAS) Hits New 52-Week HighStill a Buy? - MarketBeat
Erasca stock hits 52-week high at $10.71 By Investing.com - Investing.com Nigeria
Erasca stock hits 52-week high at $10.71 - Investing.com India
Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock? - Barchart.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Mizuho initiates Erasca (ERAS) with 'outperform' rating and $16 PT - MSN
Mizuho Initiates Erasca (ERAS) With 'Outperform' Rating and $16 PT - Finviz
Mizuho Initiates Erasca (ERAS) With ‘Outperform’ Rating and $16 PT - Insider Monkey
11 Best Performing Stocks in the Last 12 Months - Insider Monkey
Guggenheim more than doubles Erasca (ERAS) PT following clinical progress and updated pipeline models - MSN
Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models - Finviz
Erasca extends cash runway after upsized public offering - TipRanks
Erasca, Inc. Closes Upsized Public Offering - TradingView
Does Erasca’s US$225 Million Equity Raise and ERAS-0015 Data Change The Bull Case For ERAS? - simplywall.st
10 New Stocks on the Rise - Insider Monkey
FY2027 Earnings Forecast for Erasca Issued By HC Wainwright - MarketBeat
Guggenheim raises Erasca stock price target to $12 on RAS inhibitor progress - Investing.com UK
Biotech Fundraising A Good Sign For Public Markets - Law360
Erasca stock price target raised to $15 from $11 at H.C. Wainwright - Investing.com
Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? - Benzinga
Morgan Stanley Raises Price Target on Erasca to $10 From $4, Keeps Equalweight Rating - marketscreener.com
Fundamentals Check: How does Erasca Inc perform in inflationary periods2025 Price Momentum & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Erasca completes $258.8 million public offering of common stock By Investing.com - Investing.com Australia
Erasca completes $258.8 million public offering of common stock - Investing.com India
Investor Mood: Should I average down on Erasca Inc stock2025 Major Catalysts & Stock Portfolio Risk Control - baoquankhu1.vn
Erasca Closes Public Offering - marketscreener.com
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Erasca Announces Major Underwritten Public Equity Offering - The Globe and Mail
Erasca stock hits 52-week high at 10.46 USD By Investing.com - Investing.com Nigeria
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):